Pricing Log in Create free account

Bicycle Therapeutics PLC Sponsored ADR (BCYC) vs Atrium Therapeutics, Inc. (RNA)

Bicycle Therapeutics PLC Sponsored ADR and Atrium Therapeutics, Inc. are both Biotechnology companies. Bicycle Therapeutics PLC Sponsored ADR and Atrium Therapeutics, Inc. are of similar size ($185.8M and $182.5M). Bicycle Therapeutics PLC Sponsored ADR has the higher net margin (−169.8% vs −203.7%) and the lower return on invested capital (−279.8% vs 0.00%). Across the 15 metrics below, Bicycle Therapeutics PLC Sponsored ADR leads on 9 and Atrium Therapeutics, Inc. on 6.

Valuation

Metric BCYC RNA Biotechnology median
P/E n/m n/m 10.60
P/S 3.02 5.08 9.40
P/B 0.50 0.66 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA 1.28 2.03 0.66
EV/Sales (2.35) (4.33) 9.02
Earnings yield (56.22%) (40.03%) (32.88%)
Free cash flow yield (70.08%) (40.71%) (23.13%)

Profitability

Metric BCYC RNA Biotechnology median
Gross margin 100.00% 100.00% 68.51%
Operating margin (189.43%) (214.60%) 0.00%
Net margin (169.75%) (203.67%) 0.00%
Free cash flow margin (211.95%) (206.99%) 0.00%
Return on equity (25.24%) 0.00% (51.96%)
Return on assets (21.30%) (40.74%) (46.06%)
Return on invested capital (279.76%) 0.00% 0.00%

Growth

Metric BCYC RNA Biotechnology median
Revenue growth (TTM) 194.75% — 6.76%
EPS growth (last fiscal year) (8.97%) — 29.88%
Revenue growth, 5-year CAGR 47.52% 22.54% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric BCYC RNA Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 12.09 8.73 4.97
Net debt to EBITDA 2.61 9.08 1.01

Dividend

Metric BCYC RNA Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric BCYC RNA Biotechnology median
Market cap 182.52m 185.78m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack